Abstract Library

#4069 Impact of nutritional status in the quality of life (QoL) of patients with advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in Spain: NUTRIGETNE Study

Introduction: Prevalence of malnutrition and sarcopenia is high among patients with advanced GEP-NENs and may significantly decrease response to therapy and impair QoL.

Conference:

Presenting Author:

Authors: Del Olmo-García M, Garcia-Carbonero R, Hernando J, Pérez-Wert P, Suarez Gutiérrez L,

Keywords: nutritional status, Gastroenteropancreatic, Neuroendocrine neoplasm, Sarcopenia, Malnutrition,

#3777 The value of the Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) in patients with neuroendocrine tumors (NET) treated with 177Lutetium-DOTATATE (177Lu)

Introduction: The correlation between clinical benefit and toxicity is an unmet need in daily clinical practice. PRO-CTCAE is a questionnaire that allows subjective and detailed symptom reporting directly from patients. This prospective, multicentre study will apply PRO-CTCAE in a cohort of consecutive adult patients with metastatic NET on treatment with 177Lu.

Conference:

Presenting Author: Hernando J

Authors: Carmona Alonso A, Hernando Cubero J, Garcia Alvarez A, Roca-Herrera M, Garcia Burillo A,

Keywords: TNE, 177Lu, PRO-CTCAE,

#3578 Optimal PLAnning of treatment and research of Neuroendocrine Tumors (NETs) in Australia: The PLANET registry and patient reported outcomes via PLANET App

Introduction: Neuroendocrine Neoplasms (NENs) are challenging to diagnose and manage due to their varied behaviour. Despite usually having an indolent course, they are often metastatic at diagnosis and can be associated with significant long-term morbidity and impaired quality-of-life (QOL). The PLANET registry was established to collate clinical data from tertiary NET centres and integrate these with real-time patient reported outcomes (PROs) enabled by the smartphone-based PLANET App.

Conference:

Presenting Author: Leyden S

Authors: Leyden S, Cummins M, Pavlakis N, Ransom D, Price T,

Keywords: data, PROMS, PROs, QOLs, real-world data,

#3065 Intensive Personalized Program for Daily Living with Neuroendocrine Neoplasms as a Chronic Disease: Preliminary Results

Introduction: Introduction: Neuroendocrine neoplasms (NENs) are increasingly viewed as chronic diseases as a result of more effective treatments and procedures. As with any life changing events, patient and family transition to a new “normal” requires attitudinal adjustments. The Intensive Personalized Program for Daily Living with Neuroendocrine Neoplasms is a pilot program transitioning patients and their primary familial carer to a new “normal”.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Rosenberg M

Authors: Rosenberg M, Whyand T, Grozinsky-Glasberg S,

Keywords: QoL, Quality of Life, NEN Dietitian, PRO, Patient Reported Outcomes,

#3017 Patient and Healthcare Practitioner Perspectives of Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review

Introduction: Somatostatin analogs (SSAs) are used to treat acromegaly and neuroendocrine tumors (NETs). Two first-generation SSAs, octreotide and lanreotide, are available to patients (pts).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cella D

Authors: Feuilly M, Jenni E, Cella D,

Keywords: neuroendocrine tumors, acromegaly, preference, patient reported outcomes,